The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.51

Today's change-0.22 -3.27%
Updated August 18 11:05 AM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.51

Today's change-0.22 -3.27%
Updated August 18 11:05 AM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc down (U.S.)$0.22

Keryx Biopharmaceuticals Inc is sharply lower today, dropping (U.S.)$0.22 or 3.27% to (U.S.)$6.51. Over the last five days, shares have gained 1.40% and 11.09% year to date. Shares have outperformed the S&P 500 by 35.12% during the last year.

Key company metrics

  • Open(U.S.) $6.64
  • Previous close(U.S.) $6.73
  • High(U.S.) $6.71
  • Low(U.S.) $6.45
  • Bid / Ask(U.S.) $6.50 / (U.S.) $6.51
  • YTD % change+11.09%
  • Volume312,102
  • Average volume (10-day)846,154
  • Average volume (1-month)1,211,520
  • Average volume (3-month)1,359,451
  • 52-week range(U.S.) $4.03 to (U.S.) $8.38
  • Beta5.29
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.70
Updated August 18 11:05 AM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-431.89%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.57%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue1512106
Total other revenue--------
Total revenue1512106
Gross profit107-5-13
Total cost of revenue551419
Total operating expense39354348
Selling / general / administrative25232321
Research & development9769
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-24-23-34-42
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-86-23-34-42
Income after tax-86-23-34-42
Income tax, total0000
Net income-86-23-34-42
Total adjustments to net income--------
Net income before extra. items-86-23-34-42
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-86-23-34-42
Inc. avail. to common incl. extra. items-86-23-34-42
Diluted net income-86-23-34-42
Dilution adjustment----00
Diluted weighted average shares113107106106
Diluted EPS excluding extraordinary itemsvalue per share-0.77-0.21-0.32-0.39
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.77-0.21-0.32-0.39